OVERVIEW

An Introduction to Amyloid-Related Imaging Abnormalities (ARIA) and Its Management - CME is organized by Alzheimer's Association.

Release: July 15, 2021
Expiration: July 01, 2023

Statement of Need / Activity Purpose:
Over the past decade, since amyloid-modifying therapeutic agents have entered Alzheimer’s disease (AD) clinical trials, the occurrence of magnetic resonance imaging (MRI) abnormalities has required careful consideration by academic investigators, pharmaceutical companies, and regulatory authorities. MRI signal changes, thought to represent “vasogenic edema” (VE) and cerebral microhemorrhage (mH), were first observed in trials with monoclonal antibodies against amyloid-beta, and have since been associated with other amyloid-modifying therapies, despite differences in the proposed mechanisms of action, indicating some commonality in effect. Amyloid-related imaging abnormalities (ARIA) have been reported in clinical trials using multiple therapeutic avenues to lower the amyloid-beta burden in Alzheimer’s disease (AD). ARIA risk will need careful consideration but can be successfully managed by clinicians and radiologists in patients using anti-amyloid treatments.

Learning Objectives:
Upon completion of this session, participants will be able to:
• Differentiate between ARIA-E and ARIA-H
• Recognize risk factors and understand what determines the evolution and course of ARIA
• Implement recommendations for appropriate clinical management of ARIA